Implications of the presence of N-glycolylneuraminic acid in recombinant therapeutic glycoproteins
- 25 July 2010
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature Biotechnology
- Vol. 28 (8), 863-867
- https://doi.org/10.1038/nbt.1651
Abstract
Recombinant glycoproteins produced in animal cell lines often bear the nonhuman sialic acid N-glycolylneuraminic acid (Neu5Gc). Ghaderi et al. show that two monoclonal antibodies in clinical use differ with respect to addition of Neu5Gc and propose that drug developers should consider the consequences of the Neu5Gc modification. Recombinant glycoprotein therapeutics produced in nonhuman mammalian cell lines and/or with animal serum are often modified with the nonhuman sialic acid N-glycolylneuraminic acid (Neu5Gc; refs. 1,2). This documented contamination has generally been ignored in drug development because healthy individuals were not thought to react to Neu5Gc (ref. 2). However, recent findings indicate that all humans have Neu5Gc-specific antibodies, sometimes at high levels3,4. Working with two monoclonal antibodies in clinical use, we demonstrate the presence of covalently bound Neu5Gc in cetuximab (Erbitux) but not panitumumab (Vectibix). Anti-Neu5Gc antibodies from healthy humans interact with cetuximab in a Neu5Gc-specific manner and generate immune complexes in vitro. Mice with a human-like defect in Neu5Gc synthesis generate antibodies to Neu5Gc after injection with cetuximab, and circulating anti-Neu5Gc antibodies can promote drug clearance. Finally, we show that the Neu5Gc content of cultured human and nonhuman cell lines and their secreted glycoproteins can be reduced by adding a human sialic acid to the culture medium. Our findings may be relevant to improving the half-life, efficacy and immunogenicity of glycoprotein therapeutics.Keywords
This publication has 44 references indexed in Scilit:
- Novel mechanism for the generation of human xeno-autoantibodies against the nonhuman sialic acid N-glycolylneuraminic acidThe Journal of Experimental Medicine, 2010
- Evidence for a novel human-specific xeno-auto-antibody response against vascular endotheliumBlood, 2009
- Carbohydrate analysis throughout the development of a protein therapeuticGlycoconjugate Journal, 2009
- Sensitive and Specific Detection of the Non-Human Sialic Acid N-Glycolylneuraminic Acid In Human Tissues and Biotherapeutic ProductsPLOS ONE, 2009
- Evidence for a human-specific mechanism for diet and antibody-mediated inflammation in carcinoma progressionProceedings of the National Academy of Sciences of the United States of America, 2008
- Diversity in specificity, abundance, and composition of anti-Neu5Gc antibodies in normal humans: Potential implications for diseaseGlycobiology, 2008
- Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-GalactoseThe New England Journal of Medicine, 2008
- N-Glycolylneuraminic Acid Deficiency in Mice: Implications for Human Biology and EvolutionMolecular and Cellular Biology, 2007
- Pharmacokinetic profile of cetuximab (Erbitux™) alone and in combination with irinotecan in patients with advanced EGFR-positive adenocarcinomaEuropean Journal of Cancer, 2005
- Sialylated carbohydrate chains of recombinant human glycoproteins expressed in Chinese hamster ovary cells contain traces of N‐glycolylneuraminic acidFEBS Letters, 1990